My TOP 3 🥉#Melanoma #ESMO26 HBI-8000 + nivolumab in advanced melanoma - phase III vs nivolumab alone.
▪️ mPFS: 11.7 vs 7.4 mo | HR 0.73
💥 ORR: 41.4% vs 32.3% (p=0.0569)
🔴 G3/4 TRAEs: 54.8% vs 17.9%
⚠️ 4 treatment-related deaths with HBI-8000
☝🏼Benefit seemed strongest in lower-burden/normal-LDH disease!
A PFS win, yes. A new standard? OS?
@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma
586 views · 6 likes · 3 reposts · 0 replies
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.orgSource: Mario Balsa · x.com